Alumis Inc. has successfully priced an upsized underwritten public offering of 17.65 million shares of common stock at $17.00 per share, resulting in gross proceeds of approximately $300.0 million before underwriting discounts, commissions and offering expenses. All shares are being sold by the company, and the transaction is expected to close on January 9, 2026, subject to customary closing conditions. In conjunction with the deal, Alumis granted the underwriters a 30-day option to purchase up to an additional 2.6475 million shares at the same public offering price, less underwriting discounts and commissions, potentially increasing the total proceeds by more than $45 million.

Morgan Stanley, Leerink Partners, Cantor Fitzgerald and Wells Fargo Securities are acting as joint book-running managers, with Baird and Oppenheimer & Co. serving as co-lead managers. The financing follows the SEC’s declaration of effectiveness for Alumis’s shelf registration on Form S-3 in August 2025 and leverages the company’s established public market capacity. Proceeds will strengthen Alumis’s balance sheet as the clinical-stage biopharmaceutical company advances its pipeline, including its lead oral TYK2 inhibitor envudeucitinib in Phase III trials for plaque psoriasis and systemic lupus erythematosus, as well as its neuroinflammatory and thyroid eye disease programs.